Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Welcome to the Expert Insights podcast and webinar series. Throughout this series, we will be evaluating the management of ovarian cancer within the UK and debating the relevance and implications of ‘hot topics’ in patient care. We will be sharing insights from key members of the ovarian cancer community with you, as we invite them to give their opinions on the latest developments in the changing treatment landscape.
Welcome to the Expert Insights podcast and webinar series. Throughout this series, we will be evaluating the management of ovarian cancer within the UK and debating the relevance and implications of ‘hot topics’ in patient care. We will be sharing insights from key members of the ovarian cancer community with you, as we invite them to give their opinions on the latest developments in the changing treatment landscape.
On-demand webinar: How is COVID-19 affecting the treatment and management of ovarian cancer?
How is COVID-19 affecting the treatment and management of ovarian cancer?
A panel of four experts in ovarian cancer discuss how the COVID-19 outbreak is affecting the management of ovarian cancer and treatment of their patients and further explore how to use the updated British Gynaecological Cancer Society (BGCS) guidelines appropriately in this climate.
Meet the panel
Jonathan Ledermann
Professor of Medical Oncology at University College London (UCL) Cancer Institute, Director of Cancer Research UK at UCL Cancer Trials Centre and Honorary Consultant in Medical Oncology UCL hospitals.
Rebecca Bowen
Consultant Medical Oncologist at the Royal United Hospitals Bath NHS Foundation trust and an honorary lecturer at the University of Bath.
Christina Fotopoulou
Consultant Gynaecological Oncologist at Queen Charlotte's and Chelsea Hospital and Professor of Practice (Gynaecological Oncology) at Imperial College London.
Marcia Hall
Consultant Medical Oncologist at Mount Vernon Cancer Centre, Hillingdon Hospital, UK and Wexham Park Hospital, UK and Professor of Translational Oncology at Brunel University London.
Episode 1: How is COVID-19 affecting the treatment and management of ovarian cancer?
How is COVID-19 affecting the treatment and management of ovarian cancer?
To download this podcast to your smartphone, please visit our mobile site.
A panel of four experts in ovarian cancer discuss how the COVID-19 outbreak is affecting the management of ovarian cancer and treatment of their patients and further explore how to use the updated British Gynaecological Cancer Society (BGCS) guidelines appropriately in this climate.
Meet the panel
Professor Jonathan Ledermann as Chair, Professor of Medical Oncology at University College London (UCL) Cancer Institute, Director of Cancer Research UK at UCL Cancer Trials Centre and Honorary Consultant in Medical Oncology UCL Hospitals.
Doctor Rebecca Bowen, Consultant Medical Oncologist at the Royal United Hospitals Bath NHS Foundation Trust and an Honorary Lecturer at the University of Bath.
Professor Marcia Hall, Consultant Medical Oncologist at Mount Vernon Cancer Centre, Hillingdon Hospital, UK and Wexham Park Hospital, UK and Professor of Translational Oncology at Brunel University London.
Doctor Agnieszka Michael, Reader in Oncology and Consultant Medical Oncologist at the University of Surrey and Royal Surrey County Hospital.
-
How to download iPhone users:
Follow the link above to subscribe directly to the podcast and listen via your Apple Podcast player.
Android users:
- Download the Pocket Casts app.
- Click "Discover" at the bottom of the screen.
- Copy and paste the link [https://gskpro.com/content/dam/global/hcpportal/en_GB/therapy-areas/oncology/xml/rssfeed.xml] in the search tab and click "Enter".
- Click Subscribe.
ZEJULA is a registered trademark of the GlaxoSmithKline group of companies.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.
